Articles tagged with Cell Therapies
Researchers found that even after highly sensitive tests detected no viable HIV, the virus quickly rebounded to substantial levels when therapy was stopped. The study suggests that eradicating HIV with current therapies is unlikely due to the presence of latent reservoirs that drugs cannot access.
Researchers found that current anti-HIV drug combinations are effective in suppressing the virus, but may not be enough to eradicate it. Studies show that residual infection persists, with some patients still showing signs of viral replication after years of treatment.
Researchers have demonstrated a faster and safer approach to cancer vaccine therapy, producing encouraging results in melanoma patients. The new method involves using circulating white blood cells and moderate doses of IL-12, showing promise for treating advanced melanoma.
A recent clinical trial found that fetal dopamine cell implants improved movement control in younger Parkinson's patients, but had no significant impact on older patients or daily activities. PET brain scans revealed increased dopamine activity in those who received the implants, but also showed more severe adverse experiences.
Ohio University researchers are producing precise measurements of neutron direction and speed to develop a new cancer treatment. This technology could lead to fewer side effects and more effective treatment options for patients.
A USC-led study shows that photopheresis reduces the number of serious organ rejections in heart transplant patients, potentially allowing for a more targeted therapy. The treatment also appears to have an anti-viral effect, reducing levels of cytomegalovirus (CMV) in the bloodstream.
Clinical trials show substantial increase in leukemia-free survival among AML patients treated with Maxamine Therapy. The treatment has been shown to prevent relapse and prolong remission while maintaining a good quality of life.
Researchers at Chiron Corporation have identified a protein molecule (CD81) that binds to the hepatitis C virus (HCV), providing clues on how the virus infects human cells. This discovery has significant implications for the development of new vaccines and therapeutics to prevent and treat chronic HCV infection.
A study led by Ohio State University found that high-dose cytarabine increased the cure rate of acute myeloid leukemia (AML) patients with core binding factor AML to nearly five times, with a 78% remission rate among those receiving the treatment. The standard dose resulted in only 16% remission rates
A study suggests that triple-drug treatment regimens are superior to less intensive therapies in maintaining HIV suppression. Researchers found that patients who switched from three-drug to two- or one-drug treatment regimens were more likely to experience a resurgence in their HIV levels.
The study aims to scientifically evaluate the benefits of a Chinese herbal formula in alleviating multiple side effects of chemotherapy in early-stage breast cancer patients. Participants will receive either the herbal formula or a placebo, with their progress monitored over 180 days.
Jay A. Levy, a UCSF professor of medicine, suggests delaying antiviral therapy for HIV infection until the CD-4 cell count falls below 400 and the viral load is above 30,000 copies per milliliter. This approach aims to avoid drug resistance and allow the immune system to recover and control the virus.
Researchers at Thomas Jefferson University used antisense therapy to prevent Burkitt's lymphoma development in laboratory mice, delaying tumor onset and decreasing its size. The strategy may also work in human patients who have relapsed after chemotherapy, with potential applications against various types of cancer.
Researchers found that HIV establishes a pool of latently infected immune system cells even with early treatment. These cells can persist for years, posing an obstacle to ultimate control and eradication of the virus. The study suggests that these reservoirs are established very early in infection.
In a Phase II study combining ONYX-015 with standard chemotherapy, nine out of ten patients experienced tumor regressions greater than 50 percent, including two complete responses. Thirty percent of patients treated with ONYX-015 alone showed significant tumor regression.
A small-scale study suggests that hyperbaric oxygen therapy can hasten recovery from stroke and save millions of dollars annually in healthcare costs. The treatment, which combines hyperbaric oxygen with diagnostic testing, may give patients an extra hour to receive treatment, potentially extending the window for intervention.
A nationwide study found a significant decline in HIV-related deaths and opportunistic infections from 1994 to mid-1997, largely due to the use of combination antiretroviral therapy including protease inhibitors. Prescription rates for combination therapy increased dramatically during this period.
A study found that HIV remains in a dormant state within CD4+ lymphocytes even after treatment with triple-drug cocktail therapy. This persistence suggests individuals must continue multiple-drug therapy to prevent reactivation of the infection.
Researchers successfully used gene therapy to grow new blood vessels in eight people with obstructed leg circulation due to atherosclerosis. The therapy, called therapeutic angiogenesis, helped improve blood flow, reduce pain and gangrene risk, and even prevented amputations.
Researchers at Duke University have developed a genetically engineered enzyme treatment to address Pompe disease, a condition causing skeletal, heart, and lung muscle destruction. The new therapy will be tested in infants with the most severe symptoms first.
Scientists at Case Western Reserve University have created artificial human chromosomes, offering a powerful tool for studying human genetics and potentially treating genetic diseases. The synthetic microchromosomes demonstrate normal centromeric activity, genetic stability, and continued gene expression.
Researchers found that self-administered IL-2 injections can produce significant increases in CD4+ T cells in HIV-infected patients. Those with higher initial CD4+ T cell counts had the best responses, with almost half sustaining increases of at least 200 cells/mm³ after one year.
A Duke University study found that patients who received magnesium during CPR were 69% less likely to experience brain damage and had better neurological outcomes. The researchers discovered that magnesium may have neuroprotective effects by preventing calcium flow into brain cells, but more trials are needed to confirm the results.
Preliminary results from ACTG 315 show that an antiretroviral drug cocktail can partially restore immune function in people with moderately advanced HIV disease. The study found increases in CD4+ T cell counts, decreased plasma levels of HIV, and improved immune response.
A study published in Science journal demonstrates the efficacy of vascular targeting agents (VTAs) in treating large solid tumors. VTAs selectively occlude tumor vasculature, causing massive tumor cell death and advanced necrosis within 72 hours. The treatment is well-tolerated and results in complete or partial tumor regressions in mice.
The University of Maryland Medical Center now offers a new therapy to prevent stroke disability using the FDA-approved drug Activase. This clot-busting treatment is administered intravenously and can significantly reduce disability risk for patients who receive it within three hours after symptom onset.